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Leptin has been shown to reduce hyperglycemia in rodent models
of type 1 diabetes. We investigated the effects of leptin adminis-
tration in University of California, Davis, type 2 diabetes mellitus
(UCD-T2DM) rats, which develop adult-onset polygenic obesity and
type 2 diabetes. Animals that had been diabetic for 2 mo were
treated with s.c. injections of saline (control) or murine leptin (0.5
mg/kg) twice daily for 1 mo. Control rats were pair-fed to leptin-
treated animals. Treatment with leptin normalized fasting plasma
glucose and was accompanied by lowered HbA1c, plasma gluca-
gon, and triglyceride concentrations and expression of hepatic
gluconeogenic enzymes compared with vehicle (P < 0.05), indepen-
dent of any effects on body weight and food intake. In addition,
leptin-treated animals exhibited marked improvement of insulin
sensitivity and glucose homeostasis compared with controls,
whereas pancreatic insulin content was 50% higher in leptin-trea-
ted animals (P < 0.05). These effects coincided with activation of
leptin and insulin signaling pathways and down-regulation of
the PKR-like endoplasmic reticulum (ER) kinase/eukaryotic transla-
tion inhibition factor 2α (PERK-eIF2α) arm of ER stress in liver,
skeletal muscle, and adipose tissue as well as increased pro-
opiomelanocortin and decreased agouti-related peptide in the hy-
pothalamus. In contrast, several markers of inﬂammation/immune
function were elevated with leptin treatment in the same tissues
(P < 0.05), suggesting that the leptin-mediated increase of insulin
sensitivity was not attributable to decreased inﬂammation. Thus,
leptin administration improves insulin sensitivity and normalizes
fasting plasma glucose in diabetic UCD-T2DM rats, independent
of energy intake, via peripheral and possibly centrally mediated
actions, in part by decreasing circulating glucagon and ER stress.
glucagon reduction | lipid lowering
Leptin is an adipocyte hormone (1) that plays a pivotal role inthe regulation of food intake and energy expenditure (2).
Accordingly, the discovery of leptin in 1994 (1) was met with high
expectations and the hope that administration of exogenous leptin
might be a useful therapeutic tool for controlling obesity. How-
ever, most obese humans are not leptin-deﬁcient (3) and are only
minimally responsive to the effects of leptin to produce weight
loss (4). This lack of efﬁcacy has been attributed to resistance to
the central effects of leptin to decrease food intake and body
adiposity (5, 6). However, further studies of the metabolic effects
of leptin in conditions in which circulating leptin concentrations
are low reveal the potential for leptin to be used as a treatment for
insulin resistance, hyperglycemia, and hypertriglyceridemia in
models of lipodystrophy (7, 8) and type 1 diabetes (9–11).
Leptin has been shown to inﬂuence glucose homeostasis. For
example, genetic leptin deﬁciency results in not only marked hy-
perphagia and obesity (1) but also severe insulin resistance, which
is reversed by administration of exogenous leptin (1, 12, 13).
Furthermore, leptin deﬁciency has been observed in models of
both untreated type 1 and type 2 diabetes (9, 14, 15), and low
leptin levels have been shown to contribute to the development
of hyperphagia (15) and insulin resistance (9).
Several studies have demonstrated marked improvement of
glucose homeostasis with systemic leptin administration in rodent
models of type 1 diabetes, independent of changes of energy in-
take or circulating insulin concentrations (11, 16, 17). Leptin has
several actions that could contribute to glucose lowering in type
1 diabetes. First, leptin administration lowers circulating glucagon
levels and decreases gluconeogenic gene expression in animals
with type 1 diabetes (11). Second, leptin signals to skeletal muscle
to increase fatty acid oxidation, resulting in lower tissue tri-
glyceride (TG) accumulation (18). Third, leptin administration
improves insulin sensitivity in rodent models of obesity and type
1 diabetes (13, 16, 19, 20). The mechanisms by which leptin
improves insulin sensitivity remain undeﬁned but may bemediated
through direct actions of leptin on peripheral tissues, such as liver
and skeletal muscle, and/or indirectly via effects in the central
nervous system to activate neural or endocrine signals to the
periphery (19–22).
Endoplasmic reticulum (ER) stress has been shown to play an
integral role in the development of insulin resistance and diabetes
(23, 24). ER stress occurs when the folding capacity of the ER is
exceeded and unfolded/misfolded proteins accumulate and lead
to the unfolded protein response, which is triggered by trans-
membrane sensors that detect unfolded proteins in the ER. These
proteins are PKR-like ER kinase (PERK), inositol-requiring en-
zyme 1α (IRE1α), and activating transcription factor (ATF) 6 (25).
Activation of PERK causes activation of eukaryotic translation
inhibition factor (eIF) 2α, which inhibits protein synthesis as part
of an adaptive response to decrease translational demands on
the ER (26). The unfolded protein response also up-regulates the
synthesis of chaperone proteins, such as binding Ig protein (BiP),
to assist with the increased misfolded protein load (27). Induction
of BiP and increased phosphorylation of PERK and eIF2α have
been shown to be early molecular markers of insulin resistance
in mouse models of obesity (23). Increased ER stress may also
contribute to decreased leptin sensitivity in obesity and diabetes
(28). Furthermore, development of ER stress within the pancreas
contributes to impairment of insulin production and β-cell apo-
ptosis in untreated diabetes (29).
The effects of leptin administration on glucose homeostasis
in polygenic models of type 2 diabetes have not been investigated
because most models of type 2 diabetes have defects in leptin re-
ceptor signaling, such as the db/dbmouse and the Zucker diabetic
fatty (ZDF) rats (30, 31). Given that leptin receptor mutations
are rare in human populations and that human obesity and type 2
diabetes are most often polygenic in origin, models such as the
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db/db mouse and ZDF rat are not representative of the patho-
genesis of type 2 diabetes in humans. In the present study, the
effects of leptin treatment of type 2 diabetes were investigated in
the University of California, Davis, type 2 diabetes mellitus (UCD-
T2DM) rat model, which develops adult-onset polygenic obesity,
insulin resistance, and marked hyperglycemia without a defect
in leptin signaling (14). Twice-daily s.c. administration of murine
leptin normalized fasting plasma glucose concentrations in dia-
betic UCD-T2DM rats. The normalization of fasting glucose was
associated with decreased circulating glucagon concentrations,
decreased expression of gluconeogenic enzymes, decreased circu-
lating lipids, and improved insulin sensitivity. Furthermore, ER
stress was decreased after leptin administration in several insulin
target tissues, which likely contributed to the effects of leptin to
improve insulin sensitivity and reduce hyperglycemia. These data
support the utility of leptin in combination with weight loss, insulin,
and/or other antihyperglycemic medications in the treatment of
type 2 diabetes mellitus.
Results
Leptin Treatment Normalizes Fasted Plasma Glucose Concentrations
Independent of Food Intake, Body Weight, and Circulating Insulin
Concentrations. Animals that had been diabetic for 2 mo were
treated with s.c. injections of saline (control) or murine leptin
(0.5 mg/kg) twice daily for 1 mo. To prevent the confounding
effects of leptin administration on body weight and food intake,
control rats were pair-fed to leptin-treated rats (Fig. 1A). Av-
erage daily food intake during the month of treatment was 42.2 ±
1.7 g/d and 40.8 ± 1.7 g/d in control and leptin-treated animals,
respectively. However, despite similar levels of food intake,
control animals exhibited a greater loss of body weight relative to
leptin-treated animals after 1 mo of treatment (control: −12 ±
2%; leptin: −5 ± 1%; P < 0.01). Thus, leptin-treated animals
were able to more effectively maintain their body weight than the
pair-fed controls were. The greater degree of weight loss in
control animals was likely the result of greater energy loss from
urinary glucose excretion. We have previously demonstrated that
untreated diabetic UCD-T2DM rats develop progressive gluco-
suria (14). Plasma leptin concentrations measured at 12 h after
the last leptin injection at 1 mo of treatment were 13.6 ± 4.8
ng/mL and 1.3 ± 0.6 ng/mL in leptin-treated and control animals,
respectively (P < 0.001) (Fig. 1C).
After 1 mo of treatment, fasting plasma glucose concen-
trations were three times higher in control animals compared
with leptin-treated animals (Fig. 1D, P < 0.001). Furthermore,
fasting plasma glucose concentrations in leptin-treated animals
were decreased by 50% compared with pretreatment values and
averaged 121 ± 15 mg/dL (P < 0.05), close to levels observed in
nondiabetic animals. Similarly, circulating HbA1c concentrations
were signiﬁcantly lower in leptin-treated animals compared with
control animals (P < 0.05), and leptin-treated animals demon-
strated a 2% decrease of HbA1c compared with pretreatment
values (P < 0.05) (Table 1). Fasting plasma insulin concen-
trations did not differ between leptin- and vehicle-treated rats;
however, fasting plasma insulin concentrations decreased in
leptin-treated animals compared with baseline values, suggesting
an improvement of insulin sensitivity (P < 0.05) (Table 1).
Leptin Treatment Decreases Circulating Glucagon Concentrations and
Gluconeogenic Enzymes and Improves Lipid Metabolism. Fasting
plasma glucagon concentrations were measured to determine
whether leptin-mediated suppression of glucagon was present and
could contribute, at least in part, to the improvement of hyper-
glycemia. After 1 mo of treatment, fasting plasma glucagon con-
centrations were lower in leptin-treated compared with control
animals (P < 0.05) (Fig. 2A). Also, fasting plasma glucagon con-
centrations were elevated from baseline values in control animals
(P < 0.01) but not in animals that received leptin. Furthermore,
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Fig. 1. Chronic leptin treatment normalizes fasting plasma glucose independent of food intake and body weight. Shown are food intake (A), body weight
(B), fasting plasma leptin (C), and fasting plasma glucose (D) in diabetic UCD-T2DM rats injected with saline or leptin (0.5 mg/kg SC) twice daily for 1 mo. ++P <
0.01 by two-way ANOVA; ***P < 0.001 compared with control by Bonferroni’s posttest; and #P < 0.05 compared with baseline by Student’s t test. Values are
expressed as mean ± SEM.
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fasting plasma glucagon concentrations at the beginning of the
insulin tolerance testing (ITT) were w50% lower in the leptin-
treated compared with control animals (control: 125 ± 27; leptin:
60 ± 5 pg/mL; P < 0.05) and did not signiﬁcantly change from
baseline during the ITT in either group. Correspondingly, phos-
phoenolpyruvate carboxykinase (PEPCK) and glucose-6-phos-
phatase (G6Pase) hepatic protein and mRNA were signiﬁcantly
lower in leptin-treated compared with control animals (Fig. 2 B
and C), reﬂecting a potential decrease in hepatic gluconeogenesis
in leptin-treated animals. Of note, pancreatic glucagon content did
not differ between treatment groups (Table 1).
Fasting plasma TG concentrations in leptin-treated animals
were lower compared with control animals and were decreased by
25% from pretreatment values (P < 0.001) (Table 1). However,
fasting plasma cholesterol, liver and skeletal muscle TG content,
and adipose depot weights did not differ between groups (Table 1
and Table S1).
Leptin Treatment Improves Glucose Homeostasis and Insulin Sensi-
tivity. To directly assess insulin sensitivity, animals were subjected
to ITT. Leptin-treated animals exhibited signiﬁcantly greater re-
duction of blood glucose after insulin injection compared with
controls (Fig. 2D). Plasma glucose concentrations in vehicle-
treated animals decreased from a baseline value of 546 ± 47 mg/
dL to 451 ± 108 mg/dL by 90 min after insulin administration. In
contrast, plasma glucose concentrations in leptin-treated animals
decreased from 432 ± 22 mg/dL to 80 ± 4 mg/dL (Fig. 2E). In
addition to improved insulin sensitivity, leptin-treated animals
demonstrated improved glucose homeostasis during oral glucose
tolerance testing (OGTT), likely related to the decrease of fasting
plasma glucose (Fig. 2F). There were no signiﬁcant differences in
insulin concentrations between leptin-treated and control animals
during the OGTT (Fig. 2G). Thus, leptin administration leads to
improved insulin sensitivity and enhanced glucose homeostasis
in UCD-T2DM rats.
Plasma Insulin-Like Growth Factor 1 (IGF1) and Corticosterone. IGF
has been shown to be elevated after leptin treatment and has
been proposed to contribute to improved insulin signaling (11).
Plasma IGF1 concentrations were decreased by w35% in con-
trol animals compared with pretreatment values (P < 0.05), but
plasma IGF1 concentrations did not differ between groups
(Table 1). Thus, IGF1 does not appear likely to have a major
role in the improvement of insulin sensitivity in response to
leptin treatment in UCD-T2DM rats.
Corticosterone has been suggested to contribute to the glu-
cose-lowering effects of central leptin signaling because gluco-
corticoid action increases hepatic glucose production (32) and
decreases insulin sensitivity (33). However, corticosterone con-
centrations did not differ between groups (P < 0.05) (Table 1).
Thus, changes of corticosterone do not appear to contribute to
the glucose-lowering effects of leptin in UCD-T2DM rats.
Activation of Leptin and Insulin Signaling Pathways. To investigate
the molecular basis for enhanced insulin sensitivity in leptin-
treated animals, we analyzed leptin and insulin signaling pathways
in peripheral tissues and leptin signaling in the central nervous
system of fasted control and leptin-treated animals. Janus kinase
2 (Jak2) and signal transducer and activator of transcription 3
(STAT3) tyrosyl phosphorylation was two- to threefold greater
in liver, skeletal muscle, and mesenteric adipose tissue in leptin-
treated animals compared with control animals, indicating acti-
vation of leptin signaling in these tissues, which may in turn
contribute to the observed improvements of insulin sensitivity
(Fig. 3). STAT3 phosphorylation was threefold higher in the
pancreas of leptin-treated animals compared with control animals
(P < 0.01); however, Jak2 phosphorylation in the pancreas tissue
did not differ between groups (Fig. 3).
Hypothalamic agouti-related peptide (AgRP) mRNA was
40% lower (P < 0.05) and pro-opiomelanocortin (POMC)
mRNA was sevenfold higher in leptin-treated compared with
control animals (P = 0.055, Fig. 3C). These results strongly
suggest that the peripherally administered leptin reached the
central nervous system and activated leptin-mediated signal-
transduction pathways.
Activation of Akt and MAPK was signiﬁcantly elevated in
several insulin-sensitive peripheral tissues. Phosphorylation of
Akt was increased by two- to threefold in mesenteric adipose,
liver, skeletal muscle, and pancreas (Fig. 3). In addition, phos-
phorylation of MAPK was increased by 78% in mesenteric adi-
pose, 30% in skeletal muscle, and 62% in pancreas compared
with control animals (Fig. 3).
Leptin Treatment Decreases the PERK-eIF2α Arm of ER Stress. ER
stress has been shown to play an integral role in the development
of insulin resistance. Thus, we measured markers of ER stress to
determine whether the leptin-mediated improvement of insulin
sensitivity corresponded with an improvement of ER stress.
Markers of the PERK pathway of ER stress were signiﬁcantly
lower in liver, skeletal muscle, mesenteric adipose, and pancreas
tissue after 1 mo of leptin treatment compared with vehicle-
treated animals. Phosphorylation of PERK and eIF2α was re-
duced by w83% in liver, w73% in skeletal muscle, w63% in
mesenteric adipose, and w40% in pancreas tissue of leptin-
treated animals compared with controls (Fig. 4). Furthermore,
BiP expression was reduced by 36% in liver, 71% in skeletal
muscle, 40% in mesenteric adipose, and 64% in pancreas tissue
of leptin-treated animals compared with controls (Fig. 4). Pan-
Table 1. Plasma hormones and metabolites, tissue TG content, and pancreatic insulin and
glucagon content
Control Leptin
Analyte Baseline 1 mo Baseline 1 mo
HbA1c, % 11.0 ± 0.6 11.0 ± 1.0 10.3 ± 0.7 8.5 ± 0.4*,#
Fasting plasma insulin, ng/mL 0.7 ± 0.1 0.6 ± 0.1 1.0 ± 0.1 0.6 ± 0.1#
Fasting plasma IGF1, ng/mL 855 ± 108 649 ± 74# 891 ± 84 791 ± 70
Fasting plasma TG, mg/dL 115 ± 4 144 ± 9# 123 ± 5 92 ± 7***,##
Fasting plasma cholesterol, mg/dL 104 ± 8 115 ± 7 112 ± 8 107 ± 6
Fasting plasma corticosterone, ng/mL 125 ± 21 191 ± 32# 118 ± 20 188 ± 24#
Fasting plasma adiponectin, μg/mL 1.9 ± 0.2 2.2 ± 0.2 2.0 ± 0.1 1.9 ± 0.1
Liver TG, mg/g liver ND 4.9 ± 0.5 ND 6.1 ± 0.9
Skeletal muscle TG, mg/g of muscle ND 2.6 ± 0.4 ND 2.6 ± 0.5
Pancreatic insulin, μg/g of pancreas ND 7.4 ± 1.5 ND 11.2 ± 1.5*
Pancreatic glucagon, ng/g of pancreas ND 934 ± 82 ND 1122 ± 113
Values are mean ± SEM (n = 11). *P < 0.05 and ***P < 0.001 compared with control by two-way ANOVA; #P <
0.05 and ##P < 0.01 compared with baseline by Student’s t test. ND, not determined.
14672 | www.pnas.org/cgi/doi/10.1073/pnas.1107163108 Cummings et al.
creatic insulin content was signiﬁcantly greater in leptin-treated
animals compared with controls after 1 mo of treatment (P <
0.05) (Table 1), which could be related to decreased ER stress
in the pancreas.
We hypothesized that the decrease of ER stress, especially in
adipocytes, may cause an increase in adiponectin production,
which could contribute to the improvement of insulin sensitivity.
However, circulating adiponectin concentrations did not differ
between groups (Table 1).
In contrast to the improvement of insulin sensitivity and ER
stress response, 1 mo of leptin treatment resulted in increased
protein levels of markers of inﬂammation/immune function, in-
cluding monocyte chemotactic protein 1 (MCP-1) and TNF-α in
liver, skeletal muscle, and mesenteric adipose tissue (Fig. S1).
Discussion
In the present study, we investigated the efﬁcacy of leptin in the
treatment of type 2 diabetes in UCD-T2DM rats, an animal
model of polygenic adult-onset obesity, insulin resistance, and
inadequate β-cell compensation leading to type 2 diabetes (12).
Twice-daily leptin administration (0.5 mg/kg) normalized fasting
plasma glucose concentrations independent of differences in food
intake or plasma insulin concentrations. Fasting plasma leptin
concentrations achieved with twice-daily administration of 0.5
mg/kg of leptin were similar to those observed in prediabetic
UCD-T2DM rats (14). Among the effects of leptin that are likely
to have contributed to the normalization of fasting plasma glu-
cose are decreased hepatic glucose production and marked im-
provement of insulin sensitivity. In addition, leptin-mediated
improvement of insulin sensitivity and hyperglycemia coincided
with decreased ER stress. This study demonstrates a beneﬁcial
effect of leptin treatment to reduce hyperglycemia in an obese,
polygenic model of type 2 diabetes.
Similar to previous studies in models of type 1 diabetes, fasting
plasma glucagon concentrations were signiﬁcantly reduced in
leptin-treated animals (9, 11, 17, 34). This reduction of glucagon
led to decreased hepatic PEPCK andG6Pase mRNA and protein,
which may have resulted in a decrease of hepatic gluconeogenesis
in leptin-treated animals and therefore to the improvement of
fasting plasma glucose concentrations in leptin-treated animals.
The increased pancreatic insulin content in leptin-treated animals
suggests that glucagon secretion was decreased in leptin-treated
animals as a paracrine effect of insulin to restrain glucagon re-
lease from pancreatic α-cells (35).
Leptin treatment potently improved insulin sensitivity, as
demonstrated by the increased response to insulin during an ITT
and increased activation of insulin signaling in liver, skeletal
muscle, and mesenteric adipose tissue. These observations are in
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agreement with several previous studies (9, 16, 17, 19). Im-
provement of insulin sensitivity with leptin treatment has been
demonstrated to be mediated both directly by peripheral leptin
signaling and indirectly by leptin signaling to the hypothalamus
and hindbrain (11, 19–22). We observed marked increases of Jak2
and STAT3 phosphorylation in liver, skeletal muscle, and adipose
tissue of leptin-treated animals compared with control animals.
These data suggest that leptin is signaling directly to peripheral
tissues to improve insulin sensitivity. Direct signaling to periph-
eral tissues and subsequent phosphorylation of Jak2 could con-
tribute to improved insulin signaling because Jak2 can activate
PI3K, a downstream mediator of insulin signaling (36). However,
these results do not exclude the possibility that central leptin
signaling also contributed to the improvement of insulin sensi-
tivity (10, 11, 17, 19, 34, 37). Furthermore, the decrease of AgRP
and increase of POMC hypothalamic mRNA strongly indicates
a component of central leptin signaling in this study that likely
contributed to the improvement of peripheral insulin sensitivity.
ER stress has been shown to play an important role in the
development of insulin resistance and type 2 diabetes (23, 28).
Furthermore, attenuation of ER stress with administration of
chemical chaperone proteins has been shown to reverse type 2
diabetes in mice (24). In this study, we show that chronic leptin
administration decreased the PERK-eIF2α subarm of ER stress
signaling in liver, skeletal muscle, and mesenteric adipose tissue,
an effect that likely contributed to the improvement of insulin
sensitivity.
In contrast, several inﬂammatory mediators, such as MCP-1
and TNF-α, were elevated in the liver, muscle, and adipose tissue
of leptin-treated animals compared with control animals. Fur-
thermore, the decrease of ER stress would be expected to result
in a decrease of inﬂammation (38). However, this increase of
circulating immune/inﬂammatory mediators may represent
a normalization of immune function, rather than the induction of
an inﬂammatory state, because leptin deﬁciency is associated
with impaired immune function, which is restored after leptin
administration (39). These data suggest that leptin-mediated
decreases of ER stress improve insulin sensitivity by mechanisms
other than decreasing inﬂammation.
Similar to previous studies, leptin treatment resulted in amarked
reduction of circulating TG (17). However, liver and skeletal
muscle TG content did not differ between groups. Although pre-
vious studies have shown that leptin treatment lowers tissue TG
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overnight, and tissues were col-
lected the following day. (A) Im-
munoblotting for phosphorylated
(pJak2) and total Jak2, phosphory-
lated (pSTAT3) and total STAT3
(Upper), phosphorylated (pAkt) and
total Akt, and phosphorylated
(pMAPK) and total MAPK (Lower) in
adipose, liver, muscle, and pancreas
tissue. (B) All blots were scanned
and quantiﬁed with FluorChem
9900. Results were quantiﬁed in
densitometric units and expressed
relative to the total protein of in-
terest. (C) Hypothalamic mRNA ex-
pression of AgRP and POMC. *P <
0.05, **P < 0.01, ***P < 0.001, and
+P = 0.055 compared with control
by Student’s t test. (n = 6 per group
for immunoblots; n = 4 per group
for hypothalamic mRNA.) Values
are expressed as mean ± SEM. Bar
graphs represent normalized data.
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Fig. 4. Attenuated PERK-eIF2α signaling in rats with chronic leptin treatment.
(A) Immunoblotting for phosphorylated [pPERK(Thr980)] and total PERK,
phosphorylated [pEiF-2α(Ser51)] and total eIF-2α, BiP, and tubulin in adipose,
liver, muscle, and pancreas tissue. (B) Results were quantiﬁed in densitometric
units and expressed relative to the total protein of interest or relative to tubulin
for BiP. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with control by
Student’s t test. (n = 6 per group.) Values are expressed as mean ± SEM.
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deposition (9), the data in this study are confounded by the pair-fed
control animals having lost a greater percentage of body weight
at 1 mo. The lack of differences in tissue TG deposition suggests
that alterations of lipid metabolism are not likely to have a major
role in the leptin-mediated improvement of insulin sensitivity in
UCD-T2DM rats. However, the decreased circulating TG reﬂects
an additional beneﬁt of leptin administration.
Leptin treatment resulted in greater pancreatic insulin content,
which may have been mediated by improvement of pancreatic
insulin signaling and by a decrease of ER stress. Insulin signaling
in the β-cell has been shown to induce β-cell proliferation (40),
and ER stress in the β-cell has been implicated in progressive
β-cell failure observed in type 2 diabetes (29). However, because
these measurements were made in whole pancreas tissue, it is
difﬁcult to ascribe the decreases of ER stress speciﬁcally to the
islet component of the pancreas.
In conclusion, chronic treatment with leptin normalizes fasting
plasma glucose in an animal model of polygenic obesity and type
2 diabetes. Decreases of circulating glucagon concentrations and
increased insulin sensitivity mediated by decreased ER stress are
likely contributors to the improvement of glucose homeostasis.
Overall, these results suggest that leptin administration could be
useful in the treatment of type 2 diabetes by improving insulin
sensitivity and common comorbidities of type 2 diabetes mellitus
such as hypertriglyceridemia.
Materials and Methods
Diets and Animals. Male UCD-T2DM rats were housed in the University of Cal-
ifornia,Davis,DepartmentofNutritionanimal facilityandmaintainedona14-h
light:10-hdarkcycle.At thetimeof intervention,animalswere6mooldandhad
beendiabetic for 2.1± 0.1mo (n= 11per group). Diabetes onsetwas deﬁned as
a nonfasted blood glucose >200 mg/dL measured (between 1400 and 1600
hours) for 2 wk consecutively in ad libitum-fed colony animals. Baseline non-
fasting blood glucose was 540 ± 11 mg/dL and 526 ± 11 mg/dL in control and
leptin groups, respectively. Animals received ground rodent chow (no. 5012;
Ralston Purina). Control animals were pair-fed to leptin-treated animals.
Control animals received s.c. saline injections (1 mL/kg), and leptin-treated
animals received s.c. murine recombinant leptin injections (0.5 mg/kg) twice
daily (0800 and 1800 hours). An ITT was conducted on a subset of three
animals per group after 2 wk of treatment. Animals were fasted for 4 h and
then received an i.p. injection of 1 U/kg regular insulin (Novolin R). After 1
mo of treatment, animals received their last injection and were fasted
overnight and an OGTT was conducted the following morning. Animals
received a 50% glucose solution (1 g/kg) by oral gavage, and blood was
collected from their tails. Animals were then euthanized 4 h later with an
overdose of pentobarbital (200 mg/kg i.p.). Tissues were dissected, weighed,
ﬂash-frozen in liquid nitrogen, and stored at −80 °C. The experimental
protocols were approved by the Institutional Animal Care and Use Com-
mittee of the University of California, Davis. Standard methods for plasma
and tissue analyses are described in detail in SI Materials and Methods.
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SI Materials and Methods
Hormone and Metabolite Proﬁles. Blood samples were collected
from animals the day before the start of treatment and at 1 mo
after treatment initiation. Animals were fasted overnight (13 h),
and samples were collected into EDTA-treated tubes. Plasma
glucose, cholesterol, and TG were measured with enzymatic
colorimetric assays (Thermo DMA). Leptin, glucagon, and adi-
ponectin were measured with rodent-speciﬁc RIAs (Millipore).
Insulin and IGF1 were measured by rat-speciﬁc ELISAs (Milli-
pore and R&D Systems). HbA1c was measured with an enzy-
matic colorimetric assay (Diazyme), and corticosterone was
measured by RIA (MP Biomedical).
Pancreatic Hormone Content and Tissue TG Content. Pancreas insulin
and glucagon extraction was performed as previously described
(1). Liver and skeletal muscle TG content were measured by using
the Folch method for lipid extraction (2) followed by spectro-
photometric measurement of TG content (Thermo Electron).
Immunoblotting. Tissues were ground in liquid nitrogen and lysed
with radioimmunoprecipitation assay (RIPA) buffer [150 mM
NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1%
SDS,and50mMTris (pH7.4)plus 5mMEDTA,1mMNaF,1mM
sodium orthovanadate, and protease inhibitors]. Lysates were
clariﬁed by centrifugation at 15,000 × g for 10 min, and protein
concentrations were determined with a bicinchoninic acid protein
assay kit (Pierce Chemical). Proteins were resolved by SDS/
PAGE and transferred to nitrocellulose membranes. Immuno-
blots were performed with indicated antibodies (Table S2). Pro-
teins were visualized with enhanced chemiluminescence (ECL;
Amersham Biosciences), and pixel intensities of immunoreactive
bands were quantiﬁed with FluorChem 9900 (Alpha Innotech).
Quantitative Real-Time PCR. Hepatic mRNA was extracted with
TRIzol reagent (Invitrogen), and hypothalamic mRNA was
extracted with TRIzol B (MRC\). cDNA was generated by using
the Reverse Transcription System (Promega). mRNA expression
was assessed by quantitative real-time PCR (hepatic: iCycler; Bio-
Rad; hypothalamic: ABI Prism 7900 HT; Applied Biosystems)
with the appropriate primers (Table S3). Hepatic mRNA was
normalized to GAPDH, and hypothalamic mRNA was normal-
ized to 18S RNA.
Statistics and Data Analyses. Data are presented as mean ± SEM.
Statistical analyses were performed with GraphPad Prism 4.00
for Windows (GraphPad Software). Body weight, food intake,
and fasting hormone and metabolite data and ITT and OGTT
data were compared by two-factor (time and treatment) re-
peated-measures ANOVA followed by post hoc analysis with
Bonferroni’s multiple-comparison test. Tissue weights, tissue TG
content, pancreatic hormone content, tissue protein, mRNA
expression, and changes from baseline in plasma hormones and
metabolites were analyzed with Student’s t test. Differences were
considered signiﬁcant at P < 0.05.
1. Cummings BP, et al. (2010) Dietary fructose accelerates the development of diabetes in
UCD-T2DM rats: Amelioration by the antioxidant, α-lipoic acid. Am J Physiol Regul
Integr Comp Physiol 298:R1343eR1350.
2. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and
puriﬁcation of total lipides from animal tissues. J Biol Chem 226:497e509.
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Fig. S1. Chronic leptin treatment increases markers of inﬂammation in peripheral tissues. (A) Immunoblotting for MCP-1, TNF-α, and tubulin in adipose, liver,
and muscle tissue. (B) Results were quantiﬁed in densitometric units, and MCP-1 and TNF-αwere expressed relative to tubulin. *P < 0.05, **P < 0.01, and ***P <
0.001 compared with control by Student’s t test. (n = 6 per group.) Values are expressed as mean ± SEM.
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Table S1. Tissue weights after 1 mo of leptin treatment
Tissue Control Leptin
Epididymal adipose depot 3.4 ± 0.5 3.9 ± 0.5
Retroperitoneal adipose depot 4.0 ± 0.7 4.6 ± 0.8
s.c. adipose depot 13.2 ± 2.5 16.4 ± 2.7
Mesenteric adipose depot 2.4 ± 0.2 2.4 ± 0.4
Total white adipose tissue 23 ± 3 27 ± 4
Heart 1.3 ± 0.1 1.4 ± 0.1
Kidney 2.2 ± 0.1 2.2 ± 0.1
Liver 17.6 ± 0.4 18.3 ± 0.4
Values are mean ± SEM (n = 11). All weights are in grams.
Table S2. Western blot antibodies
Antibody Source Host Dilution for Western blot
eIF2α Santa Cruz Biotechnology Mouse 1:1,000
Akt Santa Cruz Biotechnology Mouse 1:5,000
JNK Santa Cruz Biotechnology Mouse 1:1,000
MAPK Cell Signaling Rabbit 1:5,000
MCP-1 Santa Cruz Biotechnology Goat 1:1,000
PERK Santa Cruz Biotechnology Rabbit 1:1,000
Phospho-PERK (Thr980) Santa Cruz Biotechnology Rabbit 1:500
Phospho-Akt (Ser473) Cell Signaling Rabbit 1:10,000
Phospho-eIF2a (Ser51) Santa Cruz Biotechnology Rabbit 1:1,000
Phospho-JNK (Thr-183/Tyr-185) Santa Cruz Biotechnology Mouse 1:1,000
Phospho-MAPK (Thr-202/Tyr-204) Cell Signaling Rabbit 1:10,000
TNF-α Santa Cruz Biotechnology Goat 1:1,000
Tubulin Santa Cruz Biotechnology Mouse 1:10,000
PEPCK Santa Cruz Biotechnology Mouse 1:1,000
G6Pase Santa Cruz Biotechnology Rabbit 1:250
eIF2α, eukaryotic translation inhibition factor 2α; G6Pase, glucose-6-phosphatase; MCP-1, monocyte chemo-
tactic protein 1; PEPCK, phosphoenolpyruvate carboxykinase; PERK, PKR-like endoplasmic reticulum kinase.
Table S3. Real-time PCR primers
Gene Direction Sequence (59 to 39)
PEPCK Forward GAGGCCTCCCAACATTCAT
Reverse CTCAGAGCGTCTCGCCGGA
G6Pase Forward CAGGAGCCACACAGTTGAAACAGA
Reverse AGGGTGATTTACGTAAAATAGCAAA
GAPDH Forward ACCACAGTCCATGCCATCAC
Reverse TCCACCACCCTGTTGCTGTA
AgRP Forward AGGGCATCAGAAGGCCTGACCAGG
Reverse CATTGAAGAAGCGGCAGTAGCACGT
POMC Forward CGCCCGTGTTTCCA
Reverse TGACCCATGACGTACTTCC
AgRP, agouti-related peptide; POMC, pro-opiomelanocortin.
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